NFκB is increased in AD brain (Kitamura et al., 1997) and pharmacological inhibition of NFκB attenuates astrocyte reactivity in APP/PS1 and 5xFAD mice (Lindsay et al., 2021). Here, APP is linked to Alzheimer disease.